Comparing the effectiveness of Hypofractionated Radiotherapy with Conventional Radiotherapy in High Grade Glioma Treatment

Comparing the effectiveness of Hypofractionated Radiotherapy with Conventional Radiotherapy in High Grade Glioma Treatment : An Open Labelled Randomised Controlled Trial in a Tertiary Care Centre in Central India - NIL

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/01/061808

Enrollment

Registered

2024-01-24

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C719- Malignant neoplasm of brain, unspecified

Interventions

Intervention1: Radiation Therapy is the Comparator: We are comparing hypofractionated radiation therapy (53.4 Gy in 20 fractions) to conventional radiation therapy (60 Gy in 30 fractions) in treatment

Eligibility

Inclusion criteria

Inclusion criteria: 1 Pathologically proven high grade glioma (HGG). 2 Age = 50 years 3 Adequate routine blood investigations including complete blood count (CBC), liver function test (LFT) and renal function test (RFT)

Exclusion criteria

Exclusion criteria: Previous history of radiation to brain Patient with metastatic disease

Design outcomes

Primary

Measure	Time frame
More patients treated with hypofractionated radiotherapy schedule will be able to complete treatment when compared to patients treated with the conventional schedule. The total dose given via hypofractionated schedule will be equivalent to the dose given via conventional fractionation (calculated from BED formula), hence will show a similar response. Timepoint: at treatment completion, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks and 24 weeks post treatment completion	—

Measure

Time frame

More patients treated with hypofractionated radiotherapy schedule will be able to complete treatment when compared to patients treated with the conventional schedule. The total dose given via hypofractionated schedule will be equivalent to the dose given via conventional fractionation (calculated from BED formula), hence will show a similar response. Timepoint: at treatment completion, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks and 24 weeks post treatment completion

—

Secondary

Measure	Time frame
Patients will be followed up post treatment and treatment toxicity assessment (RTOG criteria), neurological assessment (NANO criteria) and quality of life (QoL using QLQ- BN 20 assessment form)Timepoint: Baseline, Treatment completion, 1,2,3,4,5,6 months post treatment	—

Countries

India

Contacts

Public ContactSimran

AIIMS RAIPUR

sidnanda@yahoo.com9713711888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026